HomeNTRA • NASDAQ
add
Natera Inc
Previous close
$122.35
Day range
$121.64 - $124.47
Year range
$36.90 - $133.54
Market cap
15.14B USD
Avg Volume
1.11M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Revenue | 413.35M | 58.13% |
Operating expense | 287.07M | 24.45% |
Net income | -37.46M | 66.19% |
Net profit margin | -9.06 | 78.63% |
Earnings per share | -0.30 | 69.07% |
EBITDA | -35.99M | 66.46% |
Effective tax rate | -2.44% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 887.10M | 20.54% |
Total assets | 1.52B | 21.56% |
Total liabilities | 680.47M | 4.41% |
Total equity | 836.52M | — |
Shares outstanding | 123.68M | — |
Price to book | 18.05 | — |
Return on assets | -7.35% | — |
Return on capital | -8.75% | — |
Cash Flow
Net change in cash
(USD) | Jun 2024info | Y/Y change |
---|---|---|
Net income | -37.46M | 66.19% |
Cash from operations | 3.99M | 105.08% |
Cash from investing | -32.05M | -167.92% |
Cash from financing | 11.04M | 18.60% |
Net change in cash | -17.02M | 22.78% |
Free cash flow | 6.78M | 111.62% |
About
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments in San Carlos, California and Austin, Texas. Wikipedia
Founded
Jan 1, 2004
Headquarters
Website
Employees
3,288